Cybin, Inc. receives Schedule I license to begin dosing patients in first-in-human study of CYB003. Thailand to make shroom-based medicine.
Cybin, Inc. (NYSE: CYBN) announced that it was granted a Schedule I license from the DEA to support the first-in-human Phase 1/2a clinical trial of CYB003, a proprietary deuterated psilocybin analog that is being developed for the treatment of major depressive disorder.
With this license in place, the company can now move on to begin dosing participants in its first-in-human study of CYB003. Here’s more: https://www.businesswire.com/news/home/20220817005140/en/Cybin-and-Clinilabs-Granted-Schedule-I-DEA-License-for-CYB003-Phase-12a-First-In-Human-Clinical-Trial?utm_campaign=shareaholic&utm_medium=twitter&utm_source=socialnetwork
Also this week, Thailand’s Narcotics Control Board announced that it wants to develop medicine from hallucinogenic mushrooms to help cure the nation’s depressed citizens. Check it out: https://thethaiger.com/news/national/govt-take-a-trip-to-the-shroom-to-help-thailands-depressed
Microdose ran a very interesting article this week about how researchers are finding that psychedelics can help neurons in the brain sprout new dendrites, which look like branches on a tree, to increase connections between cells. The growth of dendrites helps build and then solidify new circuits in the brain. Fascinating stuff! Here’s more: https://microdose.buzz/news/shifting-your-neuroplasticity-with-psychedelics/
Did you know mystical experiences are correlated with positive outcomes in psychedelic-assisted therapy?
The Mystical Experience Questionnaire is a list of thirty phenomena, like “Experience of unity with ultimate reality” and “Awareness of the life or living presence in all things.” A person who has just had psilocybin is asked to rate each item on a five-point scale according to how strongly they experienced it, with 0 being “not at all” and 5 being “more than any other time in my life.”
Higher scores on the Mystical Experience Questionnaire are positively correlated with better outcomes for patients undergoing psilocybin therapy. The strength of the mystical experience has been found to be a good indicator of whether a patient will be doing well a year or more after their treatment has concluded.
And it’s not just psilocybin. According to one study, “Improvement in depression/anxiety conditions were associated with greater intensity of mystical experiences and higher ratings of the spiritual significance and personal meaning of the 5-MeO-DMT experience.”
You can read more about the Mystical Experience Questionnaire here.